Wall Street's expectations appear to be that the company's slower-than-average growth is going to continue over the next few years. The problem in Starboard's view is that Kenvue's skin and beauty ...

Kenvue owns a strong portfolio of household brands like Tylenol, Benadryl and Band-Aid. Read why I continue to rate KVUE ...

Kenvue is guiding for $1.10 to $1.20 in 2024 earnings per share and 2% to 4% organic sales growth. If it achieves the ...

On Oct. 21, news broke that Starboard Value took a position in Kenvue. The firm thinks there is an opportunity to improve ...

The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Recent health news includes Amgen's launch of an Eylea biosimilar in the U.S., Slovakia's bird flu outbreak, and China's ...

Financial writer analyzes activist hedge fund CEO's call for Kenvue to revamp skincare, health, and beauty segments for ...

Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's ...

By Svea Herbst-Bayliss (Reuters) -Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its ...